Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family

[1]  T. Ludwig,et al.  Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. , 2013, Cell reports.

[2]  H. Schöler,et al.  Analysis of protein coding mutations in hiPSCs and their possible role during somatic cell reprogramming , 2013, Nature Communications.

[3]  J. Hopper,et al.  Abstract P4-13-10: DoBRCA1andBRCA2mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab).: , 2012 .

[4]  K. Belguise,et al.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells , 2012, Oncogene.

[5]  A. Altman,et al.  PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors , 2012, Front. Immun..

[6]  T. Ross.  Grace Rock's consent. , 2012, Endocrine-related cancer.

[7]  George M. Church,et al.  Elevated Coding Mutation Rate During the Reprogramming of Human Somatic Cells into Induced Pluripotent Stem Cells , 2012, Stem cells.

[8]  Peter Bouwman,et al.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. , 2011, Cancer cell.

[9]  T. Ludwig,et al.  BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity , 2011, Science.

[10]  Hiroyuki Konishi,et al.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells , 2011, Proceedings of the National Academy of Sciences.

[11]  C. Deng,et al.  Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155 , 2011, Nature Medicine.

[12]  Mitsugu Sekimoto,et al.  Reprogramming of mouse and human cells to pluripotency using mature microRNAs. , 2011, Cell stem cell.

[13]  Mudit Gupta,et al.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. , 2011, Cell stem cell.

[14]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[15]  G. Schatten,et al.  DNA Damage Responses in Human Induced Pluripotent Stem Cells and Embryonic Stem Cells , 2010, PloS one.

[16]  N. Wong,et al.  Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumour , 2010, Histopathology.

[17]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[18]  J. Jonkers,et al.  Preclinical mouse models for BRCA1-associated breast cancer , 2009, British Journal of Cancer.

[19]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[20]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[21]  Junjie Chen,et al.  PALB2 is an integral component of the BRCA complex required for homologous recombination repair , 2009, Proceedings of the National Academy of Sciences.

[22]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[23]  M. Tomishima,et al.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.

[24]  J. Fletcher,et al.  Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors , 2008, Oncogene.

[25]  G. Sonenshein,et al.  PKCθ promotes c-Rel–driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis , 2007 .

[26]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[27]  T. Graf.  Faculty Opinions recommendation of Induction of pluripotent stem cells from adult human fibroblasts by defined factors. , 2007 .

[28]  F. Couch,et al.  Response: Re: Molecular Basis for Estrogen Receptor α Deficiency in BRCA1-Linked Breast Cancer , 2007 .

[29]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[30]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[31]  E. Kroon,et al.  Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells , 2006, Nature Biotechnology.

[32]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[33]  A. Horwitz,et al.  Direct Stimulation of Transcription Initiation by BRCA1 Requires Both Its Amino and Carboxyl Termini* , 2006, Journal of Biological Chemistry.

[34]  E. Kroon,et al.  Efficient differentiation of human embryonic stem cells to definitive endoderm , 2005, Nature Biotechnology.

[35]  J. Manley,et al.  BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II. , 2005, Genes & development.

[36]  T. Nakajima,et al.  PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT‐negative tumors , 2005, Pathology international.

[37]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[38]  E. Campo,et al.  Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias , 2004, Clinical Cancer Research.

[39]  M. Hande,et al.  Collaboration of Brca1 and Chk2 in tumorigenesis. , 2004, Genes & development.

[40]  Thomas Ludwig,et al.  The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. , 2002, Current opinion in genetics & development.

[41]  J. Parvin,et al.  BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Parvin,et al.  Activation of Transcription in Vitro by the BRCA1 Carboxyl-terminal Domain* , 1999, The Journal of Biological Chemistry.

[43]  W. Miller,et al.  Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. , 1996, European journal of cancer.

[44]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[45]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[46]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[47]  S. Singletary,et al.  Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. , 1989, Cancer research.

[48]  P. Knoepfler,et al.  Induced pluripotency and oncogenic transformation are related processes. , 2013, Stem cells and development.

[49]  G. Sonenshein,et al.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. , 2007, The Journal of clinical investigation.

[50]  F. Couch,et al.  Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. , 2007, Journal of the National Cancer Institute.

[51]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.